Treatment of viral hepatitis - 2001

References

• Perrillo R P, Schiff E R, Davis G L, Bodenheimer H C, Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295–301
   PubMed Web of Science ®Google Scholar
• Davis G L, Balart L A, Schiff E R, Lindsay K, Bodenheimer H C, Jr, Perillo R P, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled study. N Engl J Med 1989; 321: 1501–6
   PubMed Web of Science ®Google Scholar
• DiBisceglie A M, Martin P M, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–10
   PubMedGoogle Scholar
• Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812–7
   PubMed Web of Science ®Google Scholar
• McHutchison J G, Gordon S C, Schiff E R, Shiffman M L, Lee W M, Rustgi V K, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl J Med 1998; 339: 1485–92
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee S S, Niederau K, Minuk G S, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2h plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32
   PubMed Web of Science ®Google Scholar
• Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy. Ann Intern Med 1997; 127: 875–81
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Davis G L, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131–7
   PubMed Web of Science ®Google Scholar
• McHutchison J G, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Di5 1999; 19: 57–65
   PubMedGoogle Scholar
• Zeuzem S, Feinman S V, Rasenack J, Heathcote E J, Lai M Y, Cane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–72
   PubMed Web of Science ®Google Scholar
• Lindsay K L, Trepo C, Heintges T, Shiffman M L, Gordon S C, Hoefs J C, et al. A randomized, double-blind trial comparing peginterferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395–403
   PubMed Web of Science ®Google Scholar
• Manns M P, McHutchison J G, Gordon S C, Rustgi V, Shiffman M L, Lee W M, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa 2b plus ribavirin for the treatment of chronic hepatitis C: results of a multicenter, randomized controlled trial. Lancet 2001, (in press)
   Google Scholar
• Fried M, Shiffman M L, Reddy K R, Smith C, Marino G, Goncales F, et al. Pegylated (40 k Da) interferon alfa-2a (PEGASYSB) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology 2001; 120(Suppl)A-55
   Google Scholar
• Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, et al. Randomized, double-blind, placebo-controlled trial of interferon alfa 2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32: 835–41
   PubMedGoogle Scholar
• Brillianti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32: 630–4
   PubMedGoogle Scholar
• McHutchison J G, Shiffman M, Wright W, Gordon S, Knox S, Ette E, et al. A 4 week trial of VX 497 (an IMPDH inhibitor) combined with interferon in previously untreated patients with chronic hepatitis C (Abstract). Hepatology 2001, (in press)
   Google Scholar
• Macejak D G, Jensen K L, Pavco P A, Colacino J M, Blatt L M. Ribozyme mediated cleavage of HCV-PV RNA results in marked degradation of the viral genome and potent antiviral effects (abstract). Hepatology 2000; 32: 385A
   Google Scholar
• McHutchison J G, Pockros P J, Nyberg L, Kwoh T J, Dorr F A. A dose-escalation study of ISIS 14803, an antisense inhibitor of HCV, in chronic hepatitis C patients (Abstract). Hepatòlogy 2001, (in press)
   Google Scholar
• Dienstag J L, Schiff E R, Wright T L, Perrillo R P, Hann H WL, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256–63
   PubMed Web of Science ®Google Scholar
• Gordon S C, Fang J W, Silverman A L, McHutchison J G, Albrecht J K. The significance of baseline serum alanine aminotransferase on disease characteristics and response to antiviral therapy in patients with chronic hepatitis C. Hepatology 2000; 32: 400–4
   PubMedGoogle Scholar
• Chien R N, Liaw Y F, Atkins M. Pretherapy alanine trans-aminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770–4
   PubMed Web of Science ®Google Scholar
• Liaw Y F, Leung N WY, Chang T T, Guan R, Tai D I, Keng-Yeen N G, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172–90
   PubMed Web of Science ®Google Scholar
• Dienstag J, Schiff E R, Mitchell M, Casey D E, Gitlin N, Lissoos G, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082–7
   PubMed Web of Science ®Google Scholar
• Lok A SF. Lamivudine therapy for chronic hepatitis B: is longer duration of treatment better. Gastroenterology 2000; 119: 263–6
   PubMedGoogle Scholar
• Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129–34
   PubMed Web of Science ®Google Scholar
• Schalm S W, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562–8
   PubMed Web of Science ®Google Scholar
• Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120: 1828–53
   PubMed Web of Science ®Google Scholar